Partner Article
Newcastle pharmaceutical company to be acquired for £230 million
Newcastle-based pharmaceutical company Aesica Pharmaceuticals Limited is to be acquired by The Board of Consort Medical plc in a £230 million deal.
The closing of the transaction, which is expected to occur in November, is conditional on the approval of Consort Medical’s shareholders and clearance by the German competition authorities.
Consort Medical plc is a UK company listed on the London Stock Exchange focused on developing and manufacturing disposable medical devices for drug delivery including inhaled, nasal and injectables products through its core operating division Bespak.
Aesica is one of Europe’s leading pharmaceutical CDMOs, providing contract development and manufacturing services for Finished Dose and Active Pharmaceutical Ingredients (“API”) to the global pharmaceutical industry.
Since the Aesica business was established in 2004, it has grown both organically and through acquisitions and has established key strategic relationships with major global blue-chip pharmaceutical companies.
CEO of Consort Medical plc, Jon Glenn, said “We are excited by the acquisition of Aesica which represents a very strong fit with our existing strategy of diversifying into adjacent markets and technologies to capture additional value in the drug/device supply chain.
“As one of Europe’s leading pharmaceutical CDMOs, Aesica is highly complementary to Bespak’s existing business and provides a number of clear strategic, competitive and value-enhancing benefits for the Enlarged Group.”
Founding CEO of Aesica, Dr Robert Hardy, said: “We are proud of what we have accomplished with Silverfleet Capital’s support in developing Aesica through a combination of organic growth, continuous process improvement and investment in capacity.
We continue to see many exciting opportunities in the pharmaceutical contract manufacturing sector and we look forward to pursuing these under the ownership of Consort Medical plc.“
Want your business, product or service to be seen regionally and nationally? Bdaily helps you get your story in front of the right audience, every day. Find out how Bdaily can help →
Join more than 55,000 subscribers by signing up to our daily bulletin each morning here.
Enjoy the read? Get Bdaily delivered.
Sign up to receive our daily bulletin, sent to your inbox, for free.
Celebrating Nissan's North East success story
Are you a meat proxy?
Engaging the five-generation workplace
Talent is an asset, not an operational resource
Taking advantage of the opportunities ahead
Accountability isn’t the enemy of empathy
Act now to avoid a last-minute tax scramble
How inner-city living can transform a city by the sea
Artificial intelligence's value is the time it gives back
Why we must break the magnetic pull of London
AI scepticism is healthy - inaction isn't
What does NPPF mean for planning gain and pricing?